beta
Trial Radar AI
Clinical Trial NCT07479355 (ECRAN-PLASMA) for Pneumonia is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Study of the Characteristics of Acute Mycoplasma Resuscitation: ECRAN-PLASMA Study 100

Active, not recruiting
Clinical Trial NCT07479355 (ECRAN-PLASMA) is an observational study for Pneumonia that is active, not recruiting. It started on 15 September 2024 with plans to enroll 100 participants. Led by Assistance Publique - Hôpitaux de Paris, it is expected to complete by 15 June 2026. The latest data from ClinicalTrials.gov was last updated on 18 March 2026.
Brief Summary
The ECRAN-PLASMA study aims to analyze the characteristics of patients with Mycoplasma pneumoniae or Chlamydia pneumoniae pneumonia hospitalized in intensive care units (ICU), continuous monitoring units (USC), or intensive pulmonary care units (USIP). It evaluates their management, prognosis, and macrolide resistance rates.
Detailed Description
The ECRAN-PLASMA study focuses on Mycoplasma pneumoniae and Chlamydia pneumoniae infections in intensive care units (ICU), continuous monitoring units (USC), and intensive pulmonary care units (USIP). It aims to better understand the epidemiology, management, and prognosis of these infections, particularly in light of the resurgence of cases following the COVID-19 pandemic and the increasing resistance to macrolides....Show More
Official Title

Study of the Characteristics of Acute Mycoplasma Resuscitation: ECRAN-PLASMA Study

Conditions
Pneumonia
Other Study IDs
  • ECRAN-PLASMA
  • APHP240404
NCT ID Number
NCT07479355
Start Date (Actual)
2024-09-15
Last Update Posted
2026-03-18
Completion Date (Estimated)
2026-06-15
Enrollment (Estimated)
100
Study Type
Observational
Status
Active, not recruiting
Keywords
Intensive Care Unit (ICU)
Intensive Respiratory Care Unit (USIP)
Intermediate Care Unit (USC)
Chlamydia pneumoniae
Mycoplasma pneumoniae
Infection
Arms / Interventions
Participant Group/ArmIntervention/Treatment
N/A
Infectious disease epidemiology
evaluation of patient management, prognosis, and macrolide resistance rates in severe Mycoplasma pneumoniae and Chlamydia pneumoniae infections.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Incidence of Severe Mycoplasma pneumoniae and Chlamydia pneumoniae Infections
Number of patients hospitalized in ICU, USC, or USIP with a confirmed diagnosis of Mycoplasma pneumoniae or Chlamydia pneumoniae.
From hospital admission to hospital discharge (up to 60 days)
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
In-hospital Mortality Rate
Proportion of patients who died during the index hospitalization among patients with confirmed infection, assessed from medical records.
From hospital admission to hospital discharge (up to 60 days)
Length of Stay in ICU and Hospital
Number of days spent in the ICU and total hospitalization duration.
From hospital admission to hospital discharge (up to 60 days)
Macrolide Resistance Rate
Percentage of patients infected with a macrolide-resistant strain.
At time of microbiological diagnosis (baseline)
Need for invasive mechanical ventilation
Proportion of patients requiring invasive mechanical ventilation during hospitalization, assessed from medical records.
From hospital admission to hospital discharge (up to 60 days)
Use of respiratory and supportive therapies
Proportion of patients receiving each therapeutic modality (oxygen therapy, non-invasive ventilation, invasive mechanical ventilation, ECMO) during hospitalization, assessed from medical records.
From hospital admission to hospital discharge (up to 60 days)
Time from Symptom Onset to ICU Admission
Time elapsed between the onset of symptoms and hospitalization in USC, USIP, or ICU.
At patient admission.
In-hospital mortality compared with other bacterial pneumonias
Difference in in-hospital mortality rates between patients with Mycoplasma or Chlamydia pneumoniae infection and patients with other bacterial pneumonias, assessed from medical records.
From hospital admission to hospital discharge (up to 60 days)
Vital status at hospital discharge
Proportion of patients alive at hospital discharge, assessed from medical records.
During hospitalization (up to 60 days)
Respiratory support at hospital discharge
Proportion of patients requiring respiratory support (oxygen therapy or mechanical ventilation) at hospital discharge, assessed from medical records.
During hospitalization (up to 60 days)
Occurrence of acute respiratory distress syndrome (ARDS)
Proportion of patients who developed acute respiratory distress syndrome during hospitalization, assessed from medical records.
From hospital admission to hospital discharge (up to 60 days)
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Screening of all patients hospitalized in Intermediate Care Units (USC), Intensive Respiratory Care Units (USIP), and Intensive Care Units (ICU)
  • Inclusion of patients who test positive for Mycoplasma pneumoniae or Chlamydia pneumoniae

  • Patients under 18 years old
Assistance Publique - Hôpitaux de Paris logoAssistance Publique - Hôpitaux de Paris967 active studies to explore
No contact data.
1 Study Locations in 1 Countries
Medecine intensive-reanimation, Le Kremlin-Bicêtre, France